NRAS and melanoma: The data thus suggested that antagonism of TRPM2 is a potential strategy to efficaciously treat melanoma patients that harbor the well-known B-raf or N-ras mutations or contain melanoma neoplasms that are drug-resistant via drug efflux pumps.